Home・Stock List・Coherus Oncology Inc

Coherus Oncology Inc

Closed

SectorHealthcare

1.33 16.67

Buy Sell

Overview

Share price change

24h

Current

Min

1.1400000000000001

Max

1.35

Key metrics
By Trading Economics
Income	-21M -59M
Sales	2M 14M
P/E Sector Avg	3.509 57.371
EPS	-0.22
Profit margin	-412.092
Employees	144
EBITDA	3.7M -30M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+478.36% upside

Dividends
By Acuity
Next Earnings	5 Nov 2026

Market Stats
By TradingEconomics
Market Cap	-44M 178M
Previous open	-15.34
Previous close	1.33

News Sentiment

By Acuity

50%

156 / 340 Healthcare

Coherus Oncology Inc Chart

Past performance is not a reliable indicator of future results.

Related News

18 Aug 2026, 23:26 UTC

Coherus BioSciences Inc is trading higher in after-market hours, despite broader market pressures from rising bond yields and elevated oil prices.

17 Aug 2026, 23:41 UTC

News

Coherus BioSciences announced a special dividend of contingent value rights, boosting shares in after-market trading following the company's strategic asset sale initiative.

14 Aug 2026, 19:31 UTC

Coherus BioSciences Inc shares are higher today, despite no specific news. Broader market sentiment includes concerns over disappointing U.S. retail sales data.

13 Aug 2026, 19:46 UTC

Social Media

Coherus BioSciences Inc shares are lower, extending a four-session decline. Despite social media optimism, the stock remains below its 20-day moving average.

12 Aug 2026, 23:01 UTC

Coherus BioSciences Inc shares are trading higher in after-market hours, despite recent declines and no specific news to explain the movement.

11 Aug 2026, 19:36 UTC

Coherus BioSciences Inc shares are lower amid broader market sentiment influenced by geopolitical tensions and upcoming U.S. inflation reports. No specific company news identified.

10 Aug 2026, 23:31 UTC

Coherus BioSciences Inc shares are higher in after-market trading, advancing from a low of 0.81% to a high of 3.25% since Monday's close.

8 Aug 2026, 00:01 UTC

Coherus BioSciences Inc shares rose in after-market hours, recovering from earlier volatility and settling higher since Friday's close despite no specific news identified.

7 Aug 2026, 23:21 UTC

Coherus BioSciences Inc shares are rising in after-market trading, following a Labor Department report that reduced expectations for a Federal Reserve rate hike.

6 Aug 2026, 23:21 UTC

Coherus BioSciences Inc shares fell in after-market trading, reflecting ongoing weakness and volatility amid a lack of specific news to explain the decline.

5 Aug 2026, 23:01 UTC

News

Coherus BioSciences shares are lower in after-market trading following a second-quarter adjusted EPS of -$0.19, despite exceeding estimates. Sales missed expectations at $14.31 million.

4 Aug 2026, 23:56 UTC

Coherus BioSciences Inc shares are higher in after-market hours, reflecting strong demand since Tuesday's close amid a narrowing U.S. trade deficit.

3 Aug 2026, 19:44 UTC

Coherus BioSciences Inc shares are higher during Monday's session, continuing a notable advance since Friday's close, despite trading below its 20-day moving average.

31 Jul 2026, 20:06 UTC

Coherus BioSciences shares are lower today, amid rising U.S. Treasury yields and crude oil prices, which have heightened inflation concerns and interest rate expectations.

30 Jul 2026, 22:46 UTC

Coherus BioSciences Inc shares are higher in after-market trading, reflecting a positive response amid broader market recovery despite no specific company news identified.

29 Jul 2026, 18:46 UTC

Macro Event

Coherus BioSciences Inc shares are lower today amid market volatility following the Federal Reserve's decision to maintain interest rates steady.

27 Jul 2026, 17:31 UTC

Coherus BioSciences Inc shares are higher during Monday's session, reflecting broader market trends amid declining oil prices that have eased inflation concerns.

23 Jul 2026, 19:56 UTC

Coherus BioSciences Inc is trading lower amid broader market concerns over corporate earnings and inflation pressures. Shares remain below their 20-day moving average.

22 Jul 2026, 18:26 UTC

Coherus BioSciences Inc shares are trading lower amid broader market pressures, remaining near the lower end of their one-month range. No specific news was identified.

21 Jul 2026, 19:41 UTC

Social Media

Coherus BioSciences Inc shares are higher as analysts set a $7 average price target, with potential for positive data readouts this month.

20 Jul 2026, 17:31 UTC

Coherus BioSciences Inc. shares are roughly flat today, showing little change since Friday's close amid routine trading activity within a one-month range.

Peer Comparison

Price change

Coherus Oncology Inc Forecast

Price Target

By TipRanks

478.36% upside

12 Months Forecast

Average 7.75 USD 478.36%

High 10 USD

Low 4 USD

Based on 5 Wall Street analysts offering 12 month price targets forCoherus Oncology Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

5 ratings

Buy

Hold

Sell

Based on 5 analysts giving stock ratings to Coherus Oncology Inc - Dist in the past 3 months.

Sentiment

By Acuity

156 / 340 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Coherus Oncology Inc

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.